NCT03816670

Brief Summary

To compare the number of retrieved oocytes in the late start CF-alfa (day 4) versus standard CF-alfa protocols (day 2) in patients undergoing IVF. The primary analysis will be also performed in specific subgroups of patients: expected poor-responders, expected normal responders and expected hyper-responders

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
113

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2017

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2018

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2018

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

January 22, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 25, 2019

Completed
Last Updated

January 25, 2019

Status Verified

January 1, 2019

Enrollment Period

1.1 years

First QC Date

January 22, 2019

Last Update Submit

January 24, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • number of retrieved oocytes

    To compare the number of retrieved oocytes in the late start CF-alfa (day 4) versus standard CF-alfa protocols (day 2) in patients undergoing IVF

    1 year

Study Arms (6)

poor responders day 2

EXPERIMENTAL

"poor responders" women stimulated with CF from day 2 of menstrual cycle

Drug: Corifollitropin Alfa

poor responders day 4

EXPERIMENTAL

"poor responders" women stimulated with CF from day 4 of menstrual cycle

Drug: Corifollitropin Alfa

normal responders day 2

EXPERIMENTAL

"normal responders" women stimulated with CF from day 2

Drug: Corifollitropin Alfa

normal responders day 4

EXPERIMENTAL

"normal responders" women stimulated with CF from day 4

Drug: Corifollitropin Alfa

high responders day 2

EXPERIMENTAL

"high responders" women stimulated with CF from day 2

Drug: Corifollitropin Alfa

high responders day 4

EXPERIMENTAL

"high responders" women stimulated with CF from day 4

Drug: Corifollitropin Alfa

Interventions

late start (day 4) vs. corifollitropin-alfa standard start (day 2)

high responders day 2high responders day 4normal responders day 2normal responders day 4poor responders day 2poor responders day 4

Eligibility Criteria

Age18 Years - 43 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • aged 18- 43 years
  • Male or tubal infertility with indication for IVF treatment
  • No PCOS
  • No previous IVF treatments in the past two months
  • No history of previous Ovarian Hyperstimulation Syndrome (OHSS)
  • No previous IVF cycle with more than 30 growing follicles ≥ 11 mm
  • Antral Follicle Count (AFC) \<20
  • No ovarian cyst nor malignant ovarian tumour, breast, uterus or central nervous cancer

You may not qualify if:

  • AMH \< 0.2 ng/ml
  • Età \> 43 anni

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Physiopathology of Reproduction and IVF Unit, S. Anna Hospital

Torino, 10126, Italy

Location

Related Publications (1)

  • Revelli A, Gennarelli G, Sestero M, Canosa S, Carosso A, Salvagno F, Pittatore G, Filippini C, Benedetto C. A prospective randomized trial comparing corifollitropin-alpha late-start (day 4) versus standard administration (day 2) in expected poor, normal, and high responders undergoing controlled ovarian stimulation for IVF. J Assist Reprod Genet. 2020 May;37(5):1163-1170. doi: 10.1007/s10815-020-01742-5. Epub 2020 Mar 18.

MeSH Terms

Interventions

follicle stimulating hormone, human, with HCG C-terminal peptide

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

January 22, 2019

First Posted

January 25, 2019

Study Start

April 1, 2017

Primary Completion

April 30, 2018

Study Completion

December 31, 2018

Last Updated

January 25, 2019

Record last verified: 2019-01

Data Sharing

IPD Sharing
Will not share

Locations